The U.S. Food and Drug Administration said last week it is withdrawing its emergency use authorization of Evusheld, a COVID-19 antibody therapy as a prevention tool, because it is unlikely to be effective against variants that are currently circulating. The FDA said the medication does not neutralize several omicron subvariants including BQ.1, BQ.1.1, BF.7, BF.11, BA.5.2.6, BA.4.6, BA.2.75.2, XBB and XBB.1.5. According to the CDC, these subvariants make up at least an estimated 90% of cases in the U.S. “This means that Evusheld is not expected to provide protection against developing COVID-19 if exposed to those variants,” the FDA said in a press release. Learn more from ABC here.
Original source can be found here.
